Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efavirenz/emtricitabine/tenofovir disoproxil fumarate - Bristol-Myers Squibb/Gilead Sciences/Merck & Co

Next Previous
X
Search
Drug Profile

Efavirenz/emtricitabine/tenofovir disoproxil fumarate - Bristol-Myers Squibb/Gilead Sciences/Merck & Co

Alternative Names: ATR; Atripla

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb; Gilead Sciences; Merck & Co
  • Class Antiretrovirals; Benzoxazines; Nucleotides; Phosphonic acids; Purines
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections

Most Recent Events

  • 02 Oct 2020 First Generic equivalent approved in USA for HIV-1 infections (Combination therapy, In adults)
  • 02 Oct 2020 First Generic equivalent approved in USA for HIV-1 infections (Monotherapy, In adults)
  • 31 Mar 2020 Gilead terminates its collaboration with Bristol-Myers Squibb for Efavirenz/emtricitabine/tenofovir disoproxil fumarate in European Union, Iceland, Liechtenstein, Norway and Switzerland

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top